Update to the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV
The Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV have been updated.
- Recommended Heplisav-B as the preferred vaccine for all people with HIV, including those who are vaccine naive or prior vaccine nonresponders.
- Included a new section on considerations of nucleos(t)ide-sparing regimens in people with past hepatitis B virus (HBV), chronic HBV, and isolated hepatitis B core antibody positivity.
- Changed the consideration for pegylated interferon to an alternative treatment used only in rare cases.
- Removed PreHevbrio since it will no longer be available in the United States.
These guidelines are published in an electronic format and updated as changes in prevention and treatment science occurs. All updates are developed by the subject matter groups listed in Appendix B. Guideline updates are reviewed by scientific content experts.
For a list of recent updates, please see What's New in the Guidelines. To view or download the guidelines, go to the Adult and Adolescent Opportunistic Infections Guidelines section of Clinicalinfo’s website. The guidelines tables and recommendations also can be downloaded as separate PDF files.
Clinicalinfo welcomes your feedback on the latest revisions to the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Please send your comments with the subject line “Adult and Adolescent Opportunistic Infection Guidelines” to HIVinfo@NIH.gov by January 6, 2025.